A. Michelotti

573 total citations
15 papers, 372 citations indexed

About

A. Michelotti is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, A. Michelotti has authored 15 papers receiving a total of 372 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Cancer Research, 9 papers in Oncology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in A. Michelotti's work include Cancer Genomics and Diagnostics (5 papers), Breast Cancer Treatment Studies (4 papers) and Lymphatic System and Diseases (4 papers). A. Michelotti is often cited by papers focused on Cancer Genomics and Diagnostics (5 papers), Breast Cancer Treatment Studies (4 papers) and Lymphatic System and Diseases (4 papers). A. Michelotti collaborates with scholars based in Italy, United States and Netherlands. A. Michelotti's co-authors include Gianluca Lopez, Nicola Fusco, Marco Invernizzi, Elisa De Carlo, Alessandra Bearz, Daniele Lorenzini, Elisa Bertoli, Alessandro Del Conte, Donatella Gambini and Alessandro de Sire and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Molecular Sciences and Radiotherapy and Oncology.

In The Last Decade

A. Michelotti

15 papers receiving 370 citations

Peers

Countries citing papers authored by A. Michelotti

Since Specialization

Citations

This map shows the geographic impact of A. Michelotti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Michelotti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Michelotti more than expected).

Fields of papers citing papers by A. Michelotti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Michelotti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Michelotti. The network helps show where A. Michelotti may publish in the future.

Co-authorship network of co-authors of A. Michelotti

This figure shows the co-authorship network connecting the top 25 collaborators of A. Michelotti. A scholar is included among the top collaborators of A. Michelotti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Michelotti. A. Michelotti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Hereditary Cancer Syndromes: A Comprehensive Review with a Visual Tool 2023 ·Genes ·Mattia Garutti, (unknown), Roberta Mazzeo, A. Michelotti, Lucia Da Ros, Alessandra Viel, Gianmaria Miolo, Alberto Zambelli, Fabio Puglisi	34
2	Proton and photon radiotherapy in stage III NSCLC: Effects on hematological toxicity and adjuvant immune therapy 2023 ·Radiotherapy and Oncology ·Francesco Cortiula, Lizza Hendriks, Robin Wijsman, Ruud Houben, (unknown), (unknown), Richard Canters, Marco Trovò, Nanna M. Sijtsema, (unknown), Mirko Unipan, (unknown), A. Michelotti, (unknown), Gerben Bootsma, (unknown), Joost J. Nuyttens, (unknown), Vicki Trier Taasti, Dirk De Ruysscher	14
3	Preoperative treatments in borderline resectable and locally advanced pancreatic cancer: Current evidence and new perspectives 2023 ·Critical Reviews in Oncology/Hematology ·(unknown), A. Michelotti, (unknown), (unknown), (unknown), (unknown), (unknown), Luisa Foltran, Michela Guardascione, Donatella Iacono, Elena Ongaro, Gianpiero Fasola, Fabio Puglisi	5
4	NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease 2022 ·International Journal of Molecular Sciences ·A. Michelotti, (unknown), Elisa Bertoli, Elisa De Carlo, Alessandro Del Conte, Alessandra Bearz	19
5	Targeted Therapy and Immunotherapy in Early-Stage Non-Small Cell Lung Cancer: Current Evidence and Ongoing Trials 2022 ·International Journal of Molecular Sciences ·(unknown), A. Michelotti, Elisa Bertoli, Elisa De Carlo, Alessandro Del Conte, Alessandra Bearz	46
6	NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome 2021 ·Cells ·A. Michelotti, (unknown), (unknown), Michela Guardascione, (unknown), Rossana Roncato, Luisa Foltran, Elena Ongaro, Fabio Puglisi	29
7	LDH as prognostic factor in second line treatment for advanced gastric cancer: The LINE study. 2021 ·Journal of Clinical Oncology ·A. Michelotti, (unknown), Elisa Sperti, Roberta Mazzeo, Carla Corvaja, (unknown), Lorenzo Gerratana, Michela Guardascione, (unknown), Silvia Buriolla, Paola Di Nardo, V. Fanotto, (unknown), Michele Bartoletti, Elisa Bertoli, (unknown), Angela Buonadonna, Massimo Di Maïo, Elena Ongaro, Fabio Puglisi	4
8	Refining neutropenia risk assessment in patients treated with first-line endocrine therapy (ET) and cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) for metastatic breast cancer (MBC) through a cell-free DNA workflow (cfDNA). 2021 ·Journal of Clinical Oncology ·(unknown), Roberta Mazzeo, Silvia Buriolla, (unknown), (unknown), Alessandra Franzoni, A. Michelotti, (unknown), (unknown), (unknown), Paola Di Nardo, Rossana Roncato, Marta Bonotto, Erika Cecchin, Barbara Belletti, Giuseppe Toffoli, Lorenzo Gerratana, Gustavo Baldassarre, Giuseppe Damante, Fabio Puglisi	2
9	Integrating Biological Advances Into the Clinical Management of Breast Cancer Related Lymphedema 2020 ·Frontiers in Oncology ·Marco Invernizzi, Gianluca Lopez, A. Michelotti, Konstantinos Venetis, Elham Sajjadi, Leticia De Mattos‐Arruda, Michele Ghidini, Letterio Runza, Alessandro de Sire, Renzo Boldorini, Nicola Fusco	19
10	Prognostic role of macrophage infiltration and monocyte-to-lymphocyte ratio in stage III colon cancer: The MIRROR study. 2020 ·Journal of Clinical Oncology ·Debora Basile, Maurizio Polano, Silvia Buriolla, Claire Gallois, Francesco Cortiula, Carla Corvaja, (unknown), A. Michelotti, (unknown), Lorenzo Gerratana, Elena Ongaro, Eva Andreuzzi, Giuseppe Toffoli, Angela Buonadonna, Maurizio Mongiat, Aziz Zaanan, Giuseppe Aprile, Vincenzo Canzonieri, Julien Taı̈eb, Fabio Puglisi	1
11	Breast Cancer Systemic Treatments and Upper Limb Lymphedema: A Risk-Assessment Platform Encompassing Tumor-Specific Pathological Features Reveals the Potential Role of Trastuzumab 2019 ·Journal of Clinical Medicine ·Marco Invernizzi, A. Michelotti, Marianna Noale, Gianluca Lopez, Letterio Runza, (unknown), (unknown), Concetta Blundo, Stefania Maggi, Donatella Gambini, Nicola Fusco	31
12	Lymphovascular invasion and extranodal tumour extension are risk indicators of breast cancer related lymphoedema: an observational retrospective study with long-term follow-up 2018 ·BMC Cancer ·Marco Invernizzi, Chiara Corti, Gianluca Lopez, A. Michelotti, (unknown), Donatella Gambini, Daniele Lorenzini, Elena Guerini‐Rocco, Stefania Maggi, Marianna Noale, Nicola Fusco	32
13	Mismatch Repair Protein Loss as a Prognostic and Predictive Biomarker in Breast Cancers Regardless of Microsatellite Instability 2018 ·JNCI Cancer Spectrum ·Nicola Fusco, Gianluca Lopez, Chiara Corti, Chiara Pesenti, Patrizia Colapietro, Giulia Ercoli, Gabriella Gaudioso, Alice Faversani, Donatella Gambini, A. Michelotti, (unknown), Concetta Blundo, Valentina Vaira, Monica Miozzo, Stefano Ferrero, Silvano Bòsari	66
14	Tackling the diversity of breast cancer related lymphedema: Perspectives on diagnosis, risk assessment, and clinical management 2018 ·The Breast ·A. Michelotti, Marco Invernizzi, Gianluca Lopez, Daniele Lorenzini, (unknown), Alessandro de Sire, Nicola Fusco	57
15	Role of luteinizing hormone-releasing hormone analog (LHRHa) triptorelin (T) in preserving ovarian function during chemotherapy for early breast cancer patients: Results of a multicenter phase III trial of Gruppo Italiano Mammella (GIM) group. 2010 ·Journal of Clinical Oncology ·Lucia Del Mastro, Luca Boni, A. Michelotti, Teresa Gamucci, N. Olmeo, M. Giordano, Stefania Gori, Ornella Garrone, Claudia Bighin, M. Venturini, (unknown)	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact